Statistical analysis performed on data obtained from all investigated 14 melanoma and 10 hematological cancer cells showed significant (p < 0.05) differences in MFI of HLA class I and ICAM-1 expression detected after treatment with guadecitabine and DAC, but not with AZA, vs. untreated cells (Tables 2, 3). This evidence concerns the gene ICAM1 and melanoma.